Heterogeneous role of the glutathione antioxidant system in modulating the response of ESFT to fenretinide in normoxia and hypoxia

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Magwere, Tapiwanashe ^a   Burchill, Susan A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; DOXORUBICIN; FENRETINIDE; GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE REDUCTASE; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; EWING SARCOMA; EWING SARCOMA FAMILY OF TUMOR; HYPOXIA; NONHUMAN; RNA INTERFERENCE; BIOLOGICAL MODEL; CELL COUNT; CELL HYPOXIA; CELL SURVIVAL; DIET SUPPLEMENTATION; DRUG SCREENING; ENZYMOLOGY; GENE SILENCING; HUMAN; IC 50; INTRACELLULAR SPACE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CELL COUNT; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DIETARY SUPPLEMENTS; DRUG SCREENING ASSAYS, ANTITUMOR; FENRETINIDE; GENE KNOCKDOWN TECHNIQUES; GLUTATHIONE; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR SPACE; MODELS, BIOLOGICAL; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SARCOMA, EWING;

EID: 82955188765     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028558     Document Type: Article

References (47)

1. Meister A, Anderson ME, (1983) Glutathione. Annu Rev Biochem 52: 711-760.
2. Balendiran GK, Dabur R, Fraser D, (2004) The role of glutathione in cancer. Cell Biochem Funct 22: 343-352.
3. Franco R, Cidlowski JA, (2009) Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 16: 1303-1314.
4. Estrela JM, Ortega A, Obrador E, (2006) Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43: 143-181.
5. Fojo T, Bates S, (2003) Strategies for reversing drug resistance. Oncogene 22: 7512-7523.
6. Wondrak GT, (2009) Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 11: 3013-3069.
7. Smith DG, Magwere T, Burchill SA, (2011) Oxidative stress and therapeutic opportunities: focus on the Ewing's sarcoma family of tumors. Expert Rev Anticancer Ther 11: 229-249.
8. Amberger-Murphy V, (2009) Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 9: 381-390.
9. DeClerck K, Elble RC, (2010) The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci 15: 213-225.
10. Batra S, Reynolds CP, Maurer BJ, (2004) Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res 64: 5415-5424.
11. Brahimi-Horn MC, Chiche J, Pouyssegur J, (2007) Hypoxia and cancer. J Mol Med 85: 1301-1307.
12. Kilic M, Kasperczyk H, Fulda S, Debatin KM, (2007) Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 26: 2027-2038.
13. Meister A, (1995) Glutathione biosynthesis and its inhibition. Methods Enzymol 252: 26-30.
14. Andrews PA, Schiefer MA, Murphy MP, Howell SB, (1988) Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact 65: 51-58.
15. Anderson CP, Reynolds CP, (2002) Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant 30: 135-140.
16. Pompella A, De Tata V, Paolicchi A, Zunino F, (2006) Expression of [gamma]-glutamyltransferase in cancer cells and its significance in drug resistance. Biochemical Pharmacology 71: 231.
17. Mackintosh C, Madoz-Gurpide J, Ordonez JL, Osuna D, Herrero-Martin D, (2010) The molecular pathogenesis of Ewing's sarcoma. Cancer Biol Ther 9: 655-667.
18. Burchill SA, (2008) Molecular abnormalities in Ewing's sarcoma. Expert Review of Anticancer Therapy 8: 1675-1687.
19. Wachtel M, Schafer BW, (2010) Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 36: 318-327.
20. Thacker MM, Temple HT, Scully SP, (2005) Current treatment for Ewing's sarcoma. Expert Review of Anticancer Therapy 5: 319-331.
21. Formelli F, Cleris L, (1993) Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 53: 5374-5376.
22. Goto H, Takahashi H, Fujii H, Ikuta K, Yokota S, (2003) N-(4-Hydroxyphenyl)retinamide (4-HPR) induces leukemia cell death via generation of reactive oxygen species. Int J Hematol 78: 219-225.
23. Malone W, Perloff M, Crowell J, Sigman C, Higley H, (2003) Fenretinide: a prototype cancer prevention drug. Expert Opin Investig Drugs 12: 1829-1842.
24. Myatt SS, Redfern CPF, Burchill SA, (2005) p38MAPK-Dependent Sensitivity of Ewing's Sarcoma Family of Tumors to Fenretinide-Induced Cell Death. Clin Cancer Res 11: 3136-3148.
25. Magwere T, Myatt SS, Burchill SA, (2008) Manipulation of oxidative stress to induce cell death in Ewing's sarcoma family of tumours. Eur J Cancer 44: 2276-2287.
26. Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, et al. (1993) Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11: 2036-2042.
27. Pienta KJ, Esper PS, Zwas F, Krzeminski R, Flaherty LE, (1997) Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am J Clin Oncol 20: 36-39.
28. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, et al. (2003) Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9: 2032-2039.
29. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, et al. (2006) Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24: 3423-3430.
30. Shentu J, Zhang B, Fan L, He Q, Yang B, et al. (2007) Anti-proliferative activity of fenretinide in human hepatoma cells in vitro and in vivo. Anticancer Drugs 18: 47-53.
31. Kang KW, Lee SJ, Kim SG, (2005) Molecular Mechanism of Nrf2 Activation by Oxidative Stress. Antioxidants & Redox Signaling 7: 1664-1673.
32. Soltaninassab SR, Sekhar KR, Meredith MJ, Freeman ML, (2000) Multi-faceted regulation of gamma-glutamylcysteine synthetase. J Cell Physiol 182: 163-170.
33. Griffith OW, (1999) Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 27: 922-935.
34. White DE, Burchill SA, (2010) Fenretinide-dependent upregulation of death receptors through ASK1 and p38alpha enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours. British journal of cancer 103: 1380-1390.
35. Myatt SS, Burchill SA, (2008) The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity. Oncogene 27: 985-996.
36. Sohn EJ, Li H, Reidy K, Beers LF, Christensen BL, et al. (2010) EWS/FLI1 Oncogene Activates Caspase 3 Transcription and Triggers Apoptosis In vivo. Cancer Res 0008-5472.CAN-0009-1993.
37. Aryee DN, Niedan S, Kauer M, Schwentner R, Bennani-Baiti IM, et al. (2010) Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Research 70: 4015-4023.
38. Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH, (2008) Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 7: 1961-1973.
39. Liu XW, Su Y, Zhu H, Cao J, Ding WJ, et al. (2010) HIF-1alpha-dependent autophagy protects HeLa cells from fenretinide (4-HPR)-induced apoptosis in hypoxia. Pharmacol Res 62: 416-425.
40. Song J, Guo X, Xie X, Zhao X, Li D, et al. (2011) Autophagy in hypoxia protects cancer cells against apoptosis induced by nutrient deprivation through a Beclin1-dependent way in hepatocellular carcinoma. Journal of Cellular Biochemistry DOI:10.1002/jcb.23274.
41. Wu JM, DiPietrantonio AM, Hsieh TC, (2001) Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 6: 377.
42. Facchinetti T, Mantovani A, Cantoni L, Cantoni R, Salmona M, (1978) Intercalation with DNA is a prerequisite for daunomycin, adriamycin and its congeners in inhibiting DNAase I. Chem Biol Interact 20: 97-102.
43. Pommier Y, Leo E, Zhang H, Marchand C, (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chemistry & biology 17: 421-433.
44. Zhou XJ, Rahmani R, (1992) Preclinical and clinical pharmacology of vinca alkaloids. Drugs 44 (Suppl 4): 1-16 discussion 66-19.
45. Silber PM, Gandolfi AJ, Brendel K, (1986) Adaptation of a gamma-glutamyl transpeptidase assay to microtiter plates. Anal Biochem 158: 68-71.
46. White CC, Viernes H, Krejsa CM, Botta D, Kavanagh TJ, (2003) Fluorescence-based microtiter plate assay for glutamate-cysteine ligase activity. Anal Biochem 318: 175-180.
47. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND, (2004) Glutathione metabolism and its implications for health. J Nutr 134: 489-492.